Description
Lipvas (Atorvastatin) 20 mg
Lipvas 20 mg is an oral tablet medicine containing the active ingredient atorvastatin. Atorvastatin belongs to the statin class of lipid-lowering medicines and is used to reduce elevated cholesterol and triglycerides and to help lower cardiovascular risk in appropriate patients.
Active Ingredient and Medicine Class
The verified active ingredient is atorvastatin calcium, which is the pharmaceutical form used in atorvastatin tablets. It is a HMG-CoA reductase inhibitor, commonly called a statin. Statins are used to lower low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins by reducing cholesterol production in the liver.
Established Medical Uses
Atorvastatin is established as an adjunct to diet for the treatment of adults with primary hyperlipidemia, hypertriglyceridemia, and primary dysbetalipoproteinemia. It is also used in heterozygous familial hypercholesterolemia in adults and in pediatric patients aged 10 years and older, and in homozygous familial hypercholesterolemia together with other LDL-C-lowering therapies, or alone if those therapies are unavailable. In addition, atorvastatin is indicated to reduce the risk of certain cardiovascular events in adults with multiple risk factors for coronary heart disease, in adults with type 2 diabetes and additional risk factors, and in adults with clinically evident coronary heart disease.
How It Works
Atorvastatin works by selectively inhibiting HMG-CoA reductase, an enzyme involved in the early step of cholesterol synthesis. This reduces the liver’s cholesterol production and increases the number of LDL receptors on liver cells, which helps remove LDL cholesterol from the bloodstream. The overall effect is a reduction in harmful cholesterol particles and, in many patients, a reduction in triglycerides as well.
Important Safety Information
Atorvastatin should not be used in people with acute liver failure, decompensated cirrhosis, or known hypersensitivity to atorvastatin or any tablet ingredient. Important precautions include the risk of muscle toxicity, including myopathy and rhabdomyolysis, especially in older adults, people with hypothyroidism, kidney impairment, or those taking interacting medicines. Clinically significant interactions are seen with strong CYP3A4 inhibitors and certain transport or lipid-lowering drugs, including some antivirals, macrolide antibiotics, azole antifungals, cyclosporine, gemfibrozil, and large amounts of grapefruit juice. Liver enzyme abnormalities may occur, and liver function should be assessed when clinically appropriate. Atorvastatin is not recommended during breastfeeding, and it may cause fetal harm during pregnancy.
Possible Side Effects
Common adverse effects reported with atorvastatin include nasopharyngitis, joint pain, diarrhea, pain in the extremities, urinary tract infection, muscle discomfort, nausea, and other gastrointestinal symptoms. Less common but clinically important reactions include elevations in liver enzymes, muscle weakness or pain, and rare cases of severe muscle injury. Rare immune-mediated necrotizing myopathy and serious hypersensitivity reactions have also been reported with statin use.
Scientific Evidence
Clinical studies and reviews have shown that atorvastatin lowers LDL cholesterol in a dose-related manner and reduces cardiovascular events in selected high-risk populations. Large trials have demonstrated benefit in patients with stable coronary disease and in patients with type 2 diabetes at elevated cardiovascular risk. These findings support its established role in lipid management and cardiovascular risk reduction, while also showing that higher-intensity therapy can increase the likelihood of certain laboratory abnormalities and muscle-related adverse effects.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It is not a substitute for the official patient leaflet, product labeling, or individualized assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed. Atorvastatin Calcium Tablets, prescribing information
- John C. LaRosa et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 2005. View scientific article
- C. W. M. Croom et al. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs, 2005. View scientific article
